Moneycontrol
HomeNewsBusinessEconomyFM Sitharaman reviews progress of Rs 3 lakh crore credit guarantee scheme for MSMEs

FM Sitharaman reviews progress of Rs 3 lakh crore credit guarantee scheme for MSMEs

The scheme is the biggest fiscal component of the Rs 20-lakh crore Self-Reliant India Mission package announced by Sitharaman last month.

June 09, 2020 / 18:12 IST
Story continues below Advertisement
File image

Finance Minister Nirmala Sitharaman on Tuesday held a review meeting on credit guarantee scheme with heads of public sector banks, and asked them to expedite loan disbursement under the Rs 3-lakh crore ECLGS for MSME sector, hit hard by coronavirus-induced lockdown. The meeting on Emergency Credit Line Guarantee Scheme (ECLGS) was held through a video conference, and the minister appreciated the efforts of banks in execution of the scheme.

"Hon'ble FM @nsitharaman Ji complimented PSBs on rapid traction for achieving sanctions of Rs 20,000 Cr under ECLGS. Also advised to maintain proactive outreach at branch level and keep Forms for ECLGS simple & formalities at minimum," Department of Financial Services said in a tweet.

Story continues below Advertisement

"PSBs to continue focus on sanction & reaching out to eligible MSMEs. To also target meeting credit needs of other businesses," it said.

Earlier in the day the ministry gave cluster wise data of loans sanction till June 8.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show